KRAS and lung cancer: Furthermore, Jiagge et al.59reported that patients of African descent with lung cancer have depleted KRAS G12C and EGFR L858R mutations, predictive of response to anti-KRAS therapies and EGFR tyrosine kinase inhibitors, thereby diminishing their response to targeted therapies.